Abortion providers, led by Planned Parenthood, last month won a court order temporarily blocking the law from taking effect until their lawsuit challenging it could be heard by the South Carolina Supreme Court. US FDA declines to approve Regeneron's higher-dose Eylea, shares tumble U.S. health regulators on Tuesday declined to approve a higher-dose version of Regeneron Pharmaceuticals' drug Eylea for treatment of a disease that is leading cause of blindness among the elderly, the company said as shares fell on the setback to its effort to defend the blockbuster treatment against a fast-gaining rival.
US health regulators on Tuesday declined to approve a higher-dose version of Regeneron s drug Eylea for treatment of a disease that is leading cause of blindness among the elderly.
(Reuters) -U.S. health regulators said on Tuesday they declined to approve a higher-dose version of Regeneron Pharmaceuticals' drug Eylea for treatment of a disease that is the leading cause of blindness among the elderly, and the company's shares fell on the setback to its effort to defend the blockbuster treatment against a fast-gaining rival. Regeneron's shares closed down 8.6% at $715.9. The U.S. Food and Drug Administration issued a complete response letter, indicating the agency has reviewed Regeneron's application and has outstanding questions.